menu
    • menu
    [{"orgOrder":0,"company":"Forbion","sponsor":"SynOx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody","year":"2024","type":"Series B Financing","leadProduct":"Emactuzumab","moa":"||CSF-1 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"10","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Anaveon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"ANV419","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"7","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"enGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Detalimogene Voraplasmid","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"7","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"F2G Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Olorofim","moa":"||DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"10","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"ARMGO Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"ARM210","moa":"||RYR2","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forbion \/ Inapplicable"},{"orgOrder":0,"company":"Forbion","sponsor":"Verdiva Bio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"Inapplicable","moa":"||GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Progentos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"5","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Kynexis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"Inapplicable","moa":"||KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"VectorY","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"4","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"LoQus23 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"4","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Inversago Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Inapplicable","moa":"||CB1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Azafaros","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"Nizubaglustat","moa":"||GBA2 protein","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"1","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Gyroscope Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"GT005","moa":"||Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Oxular","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Financing","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection, Sustained Release","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Noema Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Basimglurant","moa":"||mGlu5 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"9","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Granite Bio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Series B Financing","leadProduct":"GRT-001","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Calluna Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"Idelalisib","moa":"||PI3-kinase p110-delta subunit||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Forbion \/ Forbion"}]

    Find Clinical Drug Pipeline Developments & Deals by Forbion

    Menu

    Forbion

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GRT-001,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Recipient : Granite Bio

                            Deal Size : $100.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Granite Bio Debuts with $100 Million of Capital

                            Details : The financing aims to fund the development of Granite pipeline including GRT-001, it depletes pro-inflammatory monocytes, key drivers of autoimmunity and inflammation. It is being evaluated for IBD.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            April 24, 2025

                            Lead Product(s) : GRT-001,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Recipient : Granite Bio

                            Deal Size : $100.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRB-101,Inapplicable

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Recipient : Verdiva Bio

                            Deal Size : $411.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Verdiva Bio Launches With $410M Series A to Develop Next-Gen Therapies

                            Details : The financing aims to advance the clinical development of the company pipeline product, which includes VRB-101 an oral, once-weekly GLP-1 receptor agonist for obesity.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 09, 2025

                            Lead Product(s) : VRB-101,Inapplicable

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Recipient : Verdiva Bio

                            Deal Size : $411.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Recipient : Progentos Therapeutics

                            Deal Size : $65.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Progentos Therapeutics Closes $65 Million Series A Financing for Multiple Sclerosis

                            Details : The financing aims to fund the Progentos, which is developing first-in-class small molecules designed to induce remyelination of axons affected by multiple sclerosis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 20, 2024

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Recipient : Progentos Therapeutics

                            Deal Size : $65.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emactuzumab,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : SynOx Therapeutics

                            Deal Size : $75.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Donesta Safety Study for Menopause Completes Treatment Phase

                            Details : The proceeds will be used to advance late-stage product Emactuzumab, SynOx's potentially best-in-class CSF-1(R) inhibiting monoclonal antibody for the treatment of Tenosynovial Giant Cell Tumour.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            April 22, 2024

                            Lead Product(s) : Emactuzumab,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : SynOx Therapeutics

                            Deal Size : $75.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Recipient : LoQus23 Therapeutics

                            Deal Size : $43.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            LoQus23 Secures £35M to Advance Small Molecule Therapy for Huntington's Disease

                            Details : The proceeds from the financing will be primarily used to support the pre-clinical development and initial clinical studies of LoQus23's lead program, an allosteric small molecule MutSβ inhibitor.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 10, 2024

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Recipient : LoQus23 Therapeutics

                            Deal Size : $43.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Idelalisib,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Recipient : Calluna Pharma

                            Deal Size : $81.1 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Two biotechs Merge to Form Calluna, with €75M in Hand to Focus on Immunotherapy Antibodies

                            Details : Calluna Pharma focuses on the clinical stage lead program CAL101, which is a monoclonal antibody that neutralizes the bioactivity of S100A4 & implements DAMP protein for idiopathic pulmonary fibrosis.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 22, 2024

                            Lead Product(s) : Idelalisib,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Recipient : Calluna Pharma

                            Deal Size : $81.1 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KYN-5356,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Kynexis Therapeutics

                            Deal Size : $62.1 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Kynexis Launched to Advance Precision Therapeutics for Brain Diseases

                            Details : Through the proceeds, Kynexis will advance its lead therapeutic candidate, KYN-5356, a potential first-in-class KAT-II inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS), toward clinical development.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 11, 2023

                            Lead Product(s) : KYN-5356,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Kynexis Therapeutics

                            Deal Size : $62.1 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Basimglurant,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Recipient : Noema Pharma

                            Deal Size : $112.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Noema Pharma Raises CHF 103 Million (USD 112 Million) in Series B Financing Round Led by Forbion and Jeito Cap...

                            Details : The proceeds of the Series B financing will be used to advance Noema Pharma's clinical-stage assets including its lead compound NOE-101 (basimglurant), an mGluR5 inhibitor which is being evaluated in Phase 2b clinical trials for severe pain in TN and sei...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 03, 2023

                            Lead Product(s) : Basimglurant,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Noema Pharma

                            Deal Size : $112.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Detalimogene Voraplasmid,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : enGene

                            Deal Size : $115.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            enGene, Inc. and Forbion European Acquisition Corp. (“FEAC”, Nasdaq: FRBN) Announce Business Combination A...

                            Details : The net proceeds are expected to be used to fund the clinical development of intravesical EG-70 (detalimogene voraplasmid), a monotherapy for Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with CIS.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 17, 2023

                            Lead Product(s) : Detalimogene Voraplasmid,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : enGene

                            Deal Size : $115.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olorofim,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : F2G Limited

                            Deal Size : $70.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Oloro...

                            Details : The proceeds from the financing with Shionogi & Co., Ltd., will enable F2G to advance late-stage development and commercialization in the US of F901318 (olorofim), a novel oral antifungal therapy to treat invasive aspergillosis and other rare mold infect...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 08, 2022

                            Lead Product(s) : Olorofim,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : F2G Limited

                            Deal Size : $70.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth